HIGHOutside partySupplier
single source suppliers
“10-K Item 1A: 'We rely on third-party suppliers, including single source suppliers, to manufacture preclinical and clinical supplies of our product candidates'”
PRLD · Concentration risk · 10-K extracted
Prelude Therapeutics Incorporat (PRLD) concentration risks
Updated
The most significant concentration Prelude Therapeutics Incorporat discloses is single source suppliers, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Prelude Therapeutics Incorporat’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-19Prelude Therapeutics discloses a single material concentration exposure: reliance on third-party suppliers, including single source suppliers, to manufacture preclinical and clinical supplies of its product candidates. This is a high-share dependency exposure — no percentage split among suppliers is disclosed, but the language makes clear that for at least some inputs there is no alternative source lined up. For a clinical-stage biotech, this kind of supply dependency is common and largely a function of the company's current stage of development rather than commercial mismanagement — trial materials are typically sourced from validated, qualified suppliers rather than multiple redundant ones. Still, because it is a high-share dependency with no offsetting diversification disclosed, it is the one exposure that could materially move the verdict if a single-source manufacturing relationship were interrupted, delaying clinical timelines. No customer, geographic, or revenue-based concentration is disclosed alongside it, which is itself consistent with a pre-commercial company whose risk is concentrated upstream in its supply chain rather than downstream in its customer base.
For the engine’s reasoning on PRLD’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| PRLD● | Prelude Therapeutics Incorporat | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.